Anika Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Anika Therapeutics, Inc. (ANIK) reported Increase Decrease In Operating Lease Liability of -$2.08 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-03-17
- Anika Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2023-12-31 was -$574.00K.
- Anika Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2023-09-30 was -$527.00K.
- Anika Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2022-12-31 was -$431.00K.
- Anika Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2022-09-30 was -$290.00K.
- Anika Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$2.08M.
- Anika Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$2.15M.
- Anika Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$1.49M.
- Anika Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2021 was -$1.63M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$2.08M 10-K · filed 2025-03-17 | |||
| 2023-12-31 | -$574.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$1.10M derived: sum of 2 quarters · filed 2025-03-17 | -$2.15M 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$527.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$1.57M 10-Q · filed 2023-11-03 | ||
| 2023-06-30 | -$1.05M 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | -$431.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$721.00K derived: sum of 2 quarters · filed 2025-03-17 | -$1.49M 10-K · filed 2025-03-17 | |
| 2022-09-30 | -$290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$1.05M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | -$764.00K 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | -$1.63M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |